



Published in final edited form as:

Adv Exp Med Biol. 2009 ; 656: 85–106.

APC and its modifiers in colon cancer

Lawrence N. Kwong^{1,3} and William F. Dove^{1,2}

¹McArdle Laboratory for Cancer Research, 425G Henry Mall, University of Wisconsin–Madison, Madison, WI 53706

²Laboratory of Genetics, 425G Henry Mall, University of Wisconsin–Madison, Madison, WI 53706

Abstract

Colon cancer closely follows the paradigm of a single “gatekeeper gene.” Mutations inactivating the *APC* (adenomatous polyposis coli) gene are found in ~80% of all human colon tumors, and heterozygosity for such mutations produces an autosomal dominant colon cancer predisposition in humans and in murine models. However, this tight association between a single genotype and phenotype belies a complex association of genetic and epigenetic factors that together generate the broad phenotypic spectrum of both familial and sporadic colon cancers. In this Chapter, we give a general overview of the structure, function, and outstanding issues concerning the role of *Apc* in human and experimental colon cancer. The availability of increasingly close models for human colon cancer in genetically tractable animal species enables the discovery and eventual molecular identification of genetic modifiers of the *Apc*-mutant phenotypes, connecting the central role of *Apc* in colon carcinogenesis to the myriad factors that ultimately determine the course of the disease.

Colorectal cancer

Colorectal cancer is the second leading cause of cancer morbidity and mortality worldwide.¹ Almost half of the population will develop at least one benign adenomatous colonic polyp during life, with less than 3% of those cases going on to develop colorectal cancer. Because symptoms are rare until very late stages, most cases go undetected. Colon cancer manifests itself as polypoid growths that progress to malignancy; metastases to the lymph nodes, liver, and lung are the primary cause of death in patients with advanced disease.

In the study of colon cancer, research is divided between sporadic and familial cases. Although hereditary colon cancer predispositions make up less than 5% of all colon cancer cases worldwide, the extensive pedigree information available in such cases has provided statistical power for isolating both the underlying causes and the genetic, environmental, and dietary modifiers of the phenotypes. The relationship of sporadic to familial colon cancer is highlighted by the successful use of therapeutics such as non-steroidal anti-inflammatory drugs (NSAIDs) to treat both diseases.² At present, a combination of chemotherapy, radiation treatment, and surgery is used to treat colon cancer. The 5-year survival expectation for colon cancer patients ranges from 93% for early stages to 8% in fully advanced stages.³

In this chapter, we will introduce and review the genetics and function of the central gatekeeper gene in colon cancer: Adenomatous Polyposis Coli (*APC/Apc*)^a

Biology of the human intestine

The small intestine is composed of interdigitated villi and crypts of Lieberkühn (for a more in-depth discussion, see Sansom, this volume). The villi serve an absorptive function in the processing of food.⁴ The colon does not contain villi, but rather is composed of crypts, invaginated into a flat surface that is folded at various intervals called rugae. During human development, the adult intestine expands in part by a process of crypt fission, where entire crypts divide, producing daughter crypts.^{5,6} This process “purifies” crypts in that the early polyclonal crypts⁷ become monoclonal. Thus, each adult crypt lineage is limited to one somatic genotype. Crypt purification also occurs by stem cell succession, whereby a clone becomes dominant within the crypt. Analysis of methylation patterns in human crypts shows that stem cell succession continues over the life of an adult, as measured by random methylation changes that gradually become fixed in a crypt.⁸ An estimated 4–16 adult stem cells reside as a clonal cohort in a niche near the bottom of each crypt. As cells reach the top of the villus in the small intestine or the collar of the crypt in the colon, they undergo apoptosis and are shed into the intestinal lumen. Cells of crypts thus turn over at a high rate (every 3–5 days⁹) owing to the continual flow of newly produced cells up the crypt/villus axis (see Potten and Morris¹⁰ for a review of a classic body of work).

Intestinal epithelial stem cells can differentiate into a number of different cell types.^{11,12} Within colonic crypts lie goblet cells that secrete mucus; at the base of small intestinal crypts lie Paneth cells that provide defense and that help to maintain the gut flora. Enterocytes perform an absorptive function for nutrients crossing the epithelium and comprise up to 80% of the small intestine. Finally, rare enteroendocrine cells, comprising ~1% of the intestine, secrete hormones such as serotonin. Below the epithelial layer lies the *lamina propria*, which comprises the stromal connective and endothelial tissue that lends support and circulation to the epithelial cells. The *muscularis mucosa* lies immediately below the epithelial layer and separates it from the submucosa, which is composed of connective tissue. Below that is the *muscularis externa*, the muscle layer along which peristalsis moves food through the intestinal tract. Finally, the serosal layer marks the outermost edge of the intestine and is attached to the mesentery.

Development of human intestinal tumors

Intestinal tumors have been hypothesized to arise from the stem cells near the bottom of crypts, but other interpretations are possible, as discussed below. Accumulating evidence in various fields of cancer research supports the stem cell origin of tumors.¹³ Such research began with the study of hematopoietic stem cells, for which the genetics and quantitative biology had been well-established for several decades.¹⁴ It was noticed that the cells of hematopoietic malignancies exhibited similarities to multipotential hematopoietic precursors, particularly the ability to self-renew.¹⁵ Eventually, it was discovered that only a certain subpopulation of hematopoietic cancer cells are capable of transferring cancer to immunocompromised NOD/SCID mice.¹⁶ Recently, solid tumors have been investigated in a similar manner. For example, human breast cancers passaged serially through NOD/SCID mice show that a small number of cancer cells expressing a certain profile of surface markers are sufficient to initiate new tumors, whereas a large number of cancer cells with different profiles are not sufficient.¹⁷ Such “cancer stem cell” profiles have been shown for

^a*APC* and *Apc* are the designations for the human and murine genes, respectively; *Apc* is used herein for the function of the gene, regardless of species.

other cancer types including myeloma, brain, and prostate.^{18,19,20} Indeed recent studies have identified CD133 as a marker enriched in a self-renewing, tumor-initiating subpopulation of cells from human colonic tumors.^{21,22} Progress in the development of diagnostic cell markers will help to resolve the issue of whether the genetic event that initiates tumorigenesis necessarily occurs in stem cells proper or whether, alternatively, they can also occur in undifferentiated or dedifferentiated daughter cells.²³

The issue of tumor progenitor cells has led to a debate about whether intestinal tumors form by a “bottom-up” process originating at the stem cell niche, or by a “top-down” process originating in cells in the inter-cryptal space at the top of the crypt/villus axis. Evidence for the “top-down” hypothesis comes from monocryptal human sporadic adenomas in which dysplasia is confined to the top half of the crypt, with normal-appearing cells more basally located in the crypt.²⁴ The implication is that the dysplasia must have started at the top and grown down towards, rather than emerging from the stem cell niche. However, it is possible that the dysplasia originated in the middle of the crypt and expanded upwards. Thus, both the “bottom-up” and “top-down” models could be explained by an upwards expansion of stem cell derivatives²⁵ from the middle of the crypt, or by the transformation of daughter stem cells to becoming tumor-competent. Clearly, the molecular identification of colon cancer stem cells is needed to determine the location of the cell of origin for particular intestinal tumors.

An early stage of colonic tumorigenesis is the benign adenoma that progresses to adenocarcinoma *in situ* - tumors that have developed high-grade dysplasia but are confined to the region above the submucosa. Progression to adenocarcinomas with invasion into or beyond the submucosa can be classified using different systems. The Dukes staging system (Dukes A, B, C, D, or E) is a measure of how far the invasive front of the cancer penetrates the intestinal wall.²⁶ In the AJCC/TNM system, numbers identifying T (tumor), N (metastasis to the nodes), and M (metastasis to distant sites) provide a comprehensive view of tumor progression.²⁷ For example, a T₄N₁M₀ cancer indicates an adenocarcinoma that has invaded through the wall of the intestine and spread to 1–3 regional lymph nodes, but not yet to distant sites. Finally, the histological classification of polyps can be villous, tubulovillous, tubular, hyperplastic, or serrated. The rare villous adenoma class is believed to have the greatest potential for malignancy.²⁸ Hyperplastic and serrated polyps have traditionally been viewed as benign; however, recent evidence points to a possible hyperplastic-serrated-adenocarcinoma progression sequence that involves somatic hyperactivation of the BRAF oncogene.²⁹ The combination of these classification systems allows for a standardization of terminology among physicians. However, not all tumors fall into only one class, and even tumors in the same nominal class can behave differently between and within patients.

Discovery of APC mutations in human colon cancer

Familial adenomatous polyposis (FAP) was first described as Gardner’s syndrome³⁰ and included extracolonic manifestations such as osteomas and congenital hypertrophy of the retinal pigment epithelium (CHRPE). Over time, it became clear that different classes of FAP existed with different symptoms, of which Gardner’s syndrome was only one. For example, “classical” FAP manifests as one hundred or more polyps in the colon, usually developing by twelve years of age, whereas patients with fewer than a hundred polyps are classified as attenuated FAP (AFAP). Many extracolonic symptoms further subdivide FAP.³¹

Linkage studies and the FAP-associated interstitial 5q Herrera deletion narrowed the genetic region underlying FAP to the 5q21 subchromosomal region (Fig.1).^{32,33} The *APC* gene was

then linked to FAP concurrently by Kinzler *et al.*³⁴, Nishisho *et al.*³⁵, Joslyn *et al.*³⁶ and Groden *et al.*³⁷ *APC* mutations were subsequently found in ~80% of sporadic colorectal tumors,³⁸ confirming that Apc acts as a central gatekeeper protein in colorectal tumorigenesis. *APC* mutations and hypermethylation have also been found in various other cancer types, including pancreatic and gastric cancers.^{39,40}

Function of Apc

Soon after the discovery of the *Apc* gene, the function of the gene product came under intense scrutiny. The crucial understanding of its function came concurrently from Su *et al.*⁴¹ and Rubinfeld *et al.*⁴² who identified the relationship between Apc and the regulation of β -catenin. We now know that the central lesions in both hereditary and sporadic colon tumors result in activation of the Wnt signaling pathway (see Kennell and Cadigan, this volume). In nearly all tumors, deactivating *APC* or *GSK-3 β* mutations or stabilizing *CTNNB1* (encoding β -catenin) mutations are present.⁴³ More specifically, the canonical tumor suppressor function of Apc is to form a “destruction complex” with Axin/Axin2 and GSK-3 β that promotes the ubiquitination and subsequent proteasomal degradation of the oncogene β -catenin in the absence of Wnt signaling. Loss of Apc function results in an accumulation of β -catenin, which translocates to the nucleus and engages the Tcf/Lef transcription factor complex to activate transcription of a large number of target genes including cyclinD1, c-myc, and CRD-BP.⁴⁴ The tumorigenic consequences of unregulated β -catenin activity may be related to both the direct stimulation of cellular growth and proliferation, and to the disruption of differentiation programs.

In addition to its role in the Wnt signaling pathway, Apc also functions to promote microtubule stability in a number of cellular contexts. The impact of the disruption of this function on tumorigenesis is not well understood (see see Caldwell and Kaplan, Morrison, and Bahmanyar *et al.*, this volume). However, it is worth noting that two groups have reported that stabilized β -catenin, expressed either from a conditionally activatable allele exposed to Cre or from a transgene, is sufficient to induce intestinal polyposis in mice,^{45,46} suggesting that loss of the microtubule-binding functions of Apc is not absolutely required for early tumor formation. Furthermore, as discussed below, mice homozygous for the 1638T *Apc* allele lacking the microtubule- and EB1-binding domains of Apc, but not the β -catenin binding domains, do not develop tumors. Despite these findings, an attractive speculation is that the disruption of microtubule functions contributes to tumor progression rather than to tumor initiation. Investigation of this idea awaits analysis of the progression stages of colonic neoplasia and the construction of mouse lines in which only the C-terminus of *Apc* can be conditionally deleted.

Structure of APC

The human *APC* gene spans 58kb, with a 15-exon coding region of 8529bp encoding a 2843 amino acid (aa), 310kD protein. Several exons exist 5' of exon 1: 0.1, 0.2, 0.3,⁴⁷ BS,⁴⁸ and possibly more. The extent to which these isoforms play a role, if any, in colon cancer is unknown; many appear to be neuron-specific.⁴⁹

The canonical Apc transcript initiates at exon 1 and produces a protein with eight known functional sub-domains (Fig. 2). The majority of truncating mutations with severe phenotypes remove most of the β -catenin-binding “20 amino acid” (20aa) repeats (1256–2031aa).⁵⁰ Interestingly, more C-terminal truncations that remove only the Axin-binding SAMP repeats (1568–2053aa),⁵¹ microtubule binding repeats (2220–2597aa),⁵² EB1-binding domain (2670–2843aa), and/or PDZ domain (the C-terminal 73aa that mediates anchoring to the cytoskeleton)⁵³ generally have an attenuated phenotype. N-terminal truncations that apparently affect only the homodimerization domain (6–57aa), owing to

bypass through the use of an internal translation restart site, likewise generally give attenuated phenotypes (see Fig 1).⁵⁴ Mutations that truncate within the armadillo repeats (453–767aa) – which bind several proteins including Asef and KAP3, both involved with different aspects of cytoskeletal function^{55,56} – or within the β -catenin-binding “15 amino acid” (15aa) repeats (1021–1187aa) tend to be somewhat milder than the 20aa repeat truncations. An interesting molecular correlation in tumors was observed that may explain these findings: germline *APC* mutations in the mutation cluster region (MCR) spanning most of the 20aa repeats generally exhibit acquired loss of the wildtype allele, while *APC* mutations outside of this region generally exhibit acquired *truncating* mutations in the wildtype allele⁵⁷. Several hypotheses have been put forth: the “just-right”⁵⁸ and “loose fit”⁵⁹ hypotheses, each of which proposes that an optimal number of 15aa repeats must remain after biallelic *Apc* inactivation to produce a severe FAP phenotype. These hypotheses remain to be rigorously tested.

Genotype-phenotype correlation in FAP

One difficulty in understanding the genotype-phenotype correlation is the current lack of a comprehensive public database of FAP patients. For research on mouse models, this lack of data makes it difficult to contextualize observations in terms of the human disease. So far, a literature search has found only one large-scale attempt to compile such information, although it presents only the results of the analysis and does not make the raw data available.⁶⁰ Compounding this difficulty is that most reports on human cases do not count the multiplicity of tumors, but rather give only an estimate. Further difficulties come from differences in phenotype that may relate to whether the patient has received surgery or chemotherapeutics, and to the age of diagnosis. To address this gap temporarily, we have compiled data on 441 cases from 37 reports (see <http://mcardle.oncology.wisc.edu/dove/Data/FAP.htm>). We suggest that a curated public database be generated under the aegis of a society for gastroenterology, for easy access to vetted information of this sort.

These data lead to a conclusion different from that of Crabtree *et al.*,⁶⁰ who claim that “mutations between codons 1020 and 1169 hav[e] the mildest disease” and that the most N-terminal truncations (i.e., prior to codon 248) do not lead to an attenuated phenotype. Instead, it seems that N-terminal truncations produce the mildest disease, although mutations between codons 1020 and 1169 tend to generate fewer tumors than mutations in the classic MCR (codons 1250–1450; cf. the “loose fit” hypothesis mentioned above, which predicts that MCR mutations leave behind a more optimal number of β -catenin-binding 15aa repeats). These discrepancies could be explained by geographic ancestry, as most of the patients of Crabtree *et al.* come only from the UK, whereas our compiled data are based on reports from around the world. In this regard, it is interesting to note the significant differences in presentation of colonic cancer in patients from the Middle East compared to those from the United States,⁶¹ possibly indicative of segregating modifier alleles (see below).

Biology of the murine intestine: an introduction to murine models of colon cancer

The mouse has long been used as a model for various human diseases, due to its experimental tractability and frequently significant reflection of the human phenotype. For colon cancer, mice readily form polyps after certain chemical treatments or genetic modifications, and have been an invaluable tool for drug and modifier locus discovery, among other benefits. In the following sections, we introduce numerous well-used mouse models, as well as a novel rat model. We also discuss other animal models involving *Apc* inactivation.

One caveat in using animal models is the deviation from human biology. The murine intestine – both mouse and rat – generally resembles that of the human in both development and structure, particularly in the formation of crypts and villi in the small intestine and in the crypt architecture of the colon. However, a few major differences exist: *i)* the murine colon and small intestine are intermingled within the peritoneum, rather than separated, *ii)* the rugae of the proximal murine colon have a diagonal rather than perpendicular pattern, and *iii)* the murine cecum is proportionately much larger. The extent to which these differences affect tumorigenesis is unknown, but must be taken into consideration when extrapolating from model animals to humans.

Mouse models of intestinal cancer

The first hereditary mouse model of colon cancer was described in 1990. Efficient ENU mutagenesis of the germline of C57BL/6J (B6) mice and subsequent outcrossing to AKR/J mice identified a phenodeviant with both a circling behavior and anemia.⁶² After continually backcrossing to B6, it was noted that the anemia trait segregated separately from the circling phenotype. Dissection of the anemic mice revealed multiple lesions throughout the intestinal tract, the majority in the small intestine. Histological preparations confirmed these lesions to be adenomas. This line of mice was therefore given the name Min (Multiple intestinal neoplasia). Su and colleagues⁶³ used the link between *Apc* mutations and FAP to narrow the search for the gene underlying the Min phenotype. Sequencing of the *Apc* gene of Min mice revealed a single change – from leucine to an amber stop codon at position 850. This mutation segregated perfectly with the small intestinal phenotype of Min mice; the mutant allele was thus termed *Apc*^{Min}. Min mice have since been extensively characterized in the literature and are currently the fourth best-selling line at the Jackson Laboratory. Its popularity can be attributed in part to several properties: *i)* Along with more recent targeted *Apc* mutants, Min is the only mouse cancer model with a single genetic change that produces a fully penetrant, organ-specific, consistent, and discrete tumor phenotype. *ii)* Adenomas in Min mice develop rapidly, with lesions visible as early as two months. Tumor multiplicities are on the order of 100 per intestinal tract, providing strong statistical power. *iii)* The multiple pathways impacting tumorigenesis enable many entry points for basic or applied study (see section below on modifiers).

Many other lines of mice with targeted genetic modifications of *Apc* have since been produced. Table 1 provides a summary of mice generated with these disruptions. When heterozygous, the $\Delta 474$, $\Delta 14$, $\Delta 716$, lacZ, and $\Delta 1309$ models all give phenotypes similar to that of Min^{64,65,66,67,68} In contrast, heterozygosity for the 1638N allele results in 0–2 tumors (none in the colon)⁶⁹ while the 1638T model is tumor-free and, unlike any other truncating allele, is homozygous viable.⁷⁰ Each of these two alleles truncates the protein at amino acid 1638; however, 1638N has only approximately 2% the transcript expression level of wild type *Apc* while 1638T has the full expression level. The latter observation implies that the C-terminus of *Apc* containing the direct microtubule and PDZ binding domains is nonessential, either for normal embryonic development or for preventing tumor initiation. However, it is important to note that the 1638T allele is not completely wildtype, since animals doubly heterozygous for 1638T and Min are embryonic lethal (as discussed by Sansom, this volume). Nonetheless, the two observations suggest that it is the reduction in *Apc* protein, not the codon 1638 truncation itself, which results in the 1638N tumor phenotypes. That a reduction in functional *Apc* protein levels leads to tumor initiation was confirmed by Li and colleagues,⁷¹ who inserted a neomycin cassette in either orientation (reverse, neoR, or forward, neoF, see Table 1) into the 13th intron of *Apc* to generate full-length hypomorphic alleles. These heterozygous mice developed fewer than two adenomas per mouse, with *Apc* protein levels and activity (as measured by β -catenin transcriptional activity) inversely correlating with tumor multiplicity. However, it is unclear whether the

neomycin/hygromycin cassette in these insertion alleles of Fodde et al and Li et al exerts a regional position effect on a neighboring gene(s) that may also contribute to the phenotype.⁷² In this context, a clear demonstration of modification of the Min phenotype by a *cis*-linked recessive lethal factor has been provided in the analysis of the modifier locus *Mom2*.⁷³

Recent advances in molecular cloning have enabled the construction of three independent conditional alleles of *Apc* in which specific exons are flanked by *loxP* sites (see Table 1): one allele that removes exon 11 upon the administration of Cre recombinase, resulting in truncation at codon 468⁷⁴ and two alleles that remove exon 14, resulting in truncation at codon 580.^{65,75} The homozygous ablation of *Apc* in various organs has broadened the understanding of the known functions of *Apc* in maintaining homeostasis in the liver, kidney, thymus, and intestine.^{76,77,74,78,79} Indeed, carcinomas are induced in the liver and kidney upon tissue-specific deletion of *Apc*. The ability to temporally control *Apc* loss, combined with a titration of Cre, opens up novel avenues for understanding the sufficiency of *Apc* loss for tumorigenesis. The recent finding that somatic *c-Myc* deletion abrogates the phenotype of concomitant *Apc* loss in the intestine confirms the power of such conditional alleles for pathway analysis.⁸⁰

Finally, chemical carcinogens such as AOM⁸¹ and ENU⁸² have been shown to induce intestinal cancer in wild type mice, and have been used as models of colon cancer.^{eg. 83}

Biology of mouse intestinal tumors

Tumors in the small intestine of the Min mouse are composed of dysplastic crypts surrounded and supported by hyperplastic villi and crypts, displaying a characteristic “rose” shape. By contrast, colonic tumors are peduncular, forming a spherical mass of dysplastic cells supported by a stromal stalk⁸⁴ Tumors have a higher mitotic index than adjacent normal tissue,⁸⁵ and crypt fission indices in Min intestines are also higher than in wild type.⁵ In contrast to the top-down/bottom-up controversy in human tumorigenesis,^{86,24} reviewed by Leedham and Wright,⁸⁷ there is little controversy over the directionality of tumor development in the Min or $\Delta 716$ mouse models: tumors begin as an outpocketing in the crypt and the dysplastic cell population expands in both directions along the crypt-villus axis.⁸⁴

Rat models of intestinal cancer

Wild type rats develop colon cancer at a very low incidence (<0.1%)⁸⁸ with the exception of the Wistar-Furth/Osaka line that spontaneously develops adenocarcinomas at a rate of 30–40%.⁸⁹ However, the genetic factors underlying this predisposition are unknown, and no recent studies have been reported. The majority of current rat models of colon cancer rely on the induction of tumors via treatment with the carcinogens AOM, DMH, or PhIP.⁹⁰ The advantages of carcinogen-treated rat models are that tumors often progress to adenocarcinomas and that tumors have not been reported in the small intestine; the disadvantages are low polyp multiplicities (<2 in F344), long tumor latencies (>10 months), and laborious carcinogen administration regimens with the potential for inconsistent dosage. Carcinogen treatments have been required in the past, owing to the lack of rat embryonic stem cells required for generating genetically engineered rats. However, the ability to generate target-selected mutations, including nonsense alleles, has recently been implemented by several laboratories.^{91,92} This capacity has been drawn upon to generate a rat strain carrying a nonsense allele in codon 1137 of *Apc*. F344 rats heterozygous for this allele develop multiple intestinal neoplasms by three months of age, predominantly in the colon, and survive in the range of one year.⁹³ The important colonic predisposition of tumorigenesis in this strain has led to its designation as Pirc: polyposis in the rat colon.

The size of the laboratory rat confers certain advantages to the Pirc model; for one, classical endoscopy can be used to monitor and biopsy colonic tumors.⁹³ In addition, microCT and microPET imaging can strengthen the annotation of each of the tumors, whose sizes – often exceeding 1cm in diameter – greatly facilitate visualization and biopsy sampling. It can significantly enhance the molecular and morphological analysis of tumor progression to annotate individual neoplasms while keeping the animal alive. While these methods are also feasible in mouse models of colon cancer, the colonic predisposition, size, and longevity of the tumor-bearing Pirc rat can provide significant advantages in developing these experimental avenues. Thus, the rat's promising utility for genetics combined with its size and feasibility for longitudinal studies of therapeutic regimes poises the Pirc kindred as a model for colon cancer that is complementary to the genetically powerful Min mouse model.

Coincidentally, the rat and mouse *Apc* loci each lie on Chromosome 18 of their respective genomes. The synteny over Chromosome (Chr) 18 is remarkably conserved between the mouse and the rat. The only difference in synteny is the most proximal 10Mb of the mouse chromosome, the homologous region of which is located on rat Chr 17. However, a more important difference between these two versions of Chr 18 is the placement of the centromere. *Apc* lies ~30Mb distal of the acrocentric mouse centromere but ~11Mb proximal of the metacentric rat centromere (Fig. 1). By contrast, in the metacentric human Chr 5, *Apc* is ~65Mb distal of the centromere.

***Apc* mutations in other organisms**

To date, *Apc* mutants have been isolated in three other experimental organisms. The *Apc*^{MCR/+} zebrafish (*Danio rerio*) develops intestinal, hepatic, and pancreatic neoplasms, demonstrating the conservation of organ-specific gene functions between vertebrate phyla.⁹⁴ *Drosophila melanogaster* lines heterozygous for mutations in either of the two *Apc* homologs, *dApc1* or *dApc2*, develop with a completely normal phenotype despite the evolutionary conservation of Wnt signaling function.⁹⁵ It is interesting to note in this context that *dApc1* can complement the function of human *Apc* in suppressing β -catenin-mediated transcription in colon cancer cell lines.⁹⁶ Finally, RNAi-induced reduction of *Caenorhabditis elegans Apr-1*, a gene homologous to the N-terminal half of human *Apc*, results in aberrations in blastomere development and endoderm specification.⁹⁷ Recent studies have linked Wnt signaling and the regulation of WRM-1, a nematode homolog of β -catenin, to Apr-1 function during critical asymmetric cell divisions in development.⁹⁸

Mechanisms of loss of heterozygosity at the *Apc* locus

Biallelic loss of *Apc* function appears to be required for tumorigenesis, but it remains open whether a heterozygous phenotype (also see below) is a necessary preliminary step to the complete loss of *Apc* function in tumors. In principle, loss of function of the wild type allele from the heterozygote can occur through any of several mechanisms, including: somatic recombination, non-disjunction with or without reduplication, coding or regulatory mutations, epigenetic silencing, or partial or full gene deletion. Early studies in Min mice demonstrated whole-chromosome loss of heterozygosity (LOH),⁹⁹ narrowing the possibilities to somatic recombination or non-disjunction. However, the acrocentric nature of mouse chromosomes makes it difficult to distinguish between somatic recombination, which results in the homozygosis of all alleles distal to the recombination site, and mitotic non-disjunction, which results in the loss of an entire homolog. Unless the centromere can be marked, each of these processes gives identical results for acrocentric, but not for metacentric chromosomes. Subsequent studies in Min mice harboring an abnormal Robertsonian metacentric Chromosome 18,¹⁰⁰ in Pirc rats with a naturally metacentric

Chromosome 18 (Fig. 1),⁹³ and in FAP patients with *Apc* truncations past codon 1286¹⁰¹ are consistent with somatic recombination; the majority of these intestinal tumors exhibit LOH limited to a single chromosome arm. Further, the genomes of the early mouse tumors appear to be stable, as assessed by FISH and karyotypic analysis.¹⁰² Somatic recombination has also been shown to be involved in LOH of other tumor suppressors in humans, such as the retinoblastoma gene *Rb1*.^{103,104}

By contrast, analysis of sporadic rather than familial human colon tumors suggests that the loss event may occur via a karyotypically unstable pathway. For example, Thiagalingam and colleagues¹⁰⁵ demonstrated that the observed single *p*-arm loss seen in 36% of tumors involved complex translocations rather than conservative somatic recombination. However, it is unclear whether the translocations were the cause of LOH, or instead were acquired during tumor progression. A study by Shih and colleagues,¹⁰⁶ showed allelic imbalance across the genome by digital SNP analysis; however, this finding will require confirmation using more current technology such as Pyrosequencing.¹⁰⁷ Another study has shown that 1638N tumors exhibit significant genomic copy number changes by comparative genomic hybridization,¹⁰⁸ this highlights differences between the 1638N and the genomically stable Min models since the 1638N phenotype may be influenced by regional position effects from the neomycin cassette.⁷² In these investigations, another open issue is whether the earliest stage in tumorigenesis is being analyzed. Thus, the debate over the role of genomic instability in colorectal tumorigenesis remains divided into two hypotheses: that instability is a prerequisite for initiation and will be observed at the “birth” of the neoplasm, or that it is acquired during dysplastic growth along the neoplastic pathway and necessary only for progression.

Mathematical models have been invoked to support each hypothesis. Nowak and colleagues¹⁰⁹ showed theoretically that chromosomal instability (CIN) can drive the majority of sporadic LOH events: a hypothesized efficient statistical “tunneling” effect of CIN could drive cells towards an equilibrated LOH population. By contrast, Komarova and Wodarz¹¹⁰ suggested that CIN would not be efficient, owing to the lag time required for the initial genomic hit to create CIN. Furthermore, Tomlinson and colleagues¹¹¹ used an evolutionary approach to stem cell statistics to show that any instability associated with colonic tumors could be explained by a selective, exponential accumulation of aberrations, rather than by a pre-existing state of instability. Such mathematical models may prove to be valuable frameworks for the design of new quantitative experimental tests.

Are some *Apc* truncation peptides dominant negative?

Several lines of evidence suggest that certain truncated *Apc* proteins might act in a dominant negative manner, either by homodimerizing to wild type *Apc* or by competing for binding to β -catenin. For example, transfection of constructs encoding the N-terminal 750aa, 1309aa, 1450aa, or 1807aa of human *Apc* into colorectal cancer cell lines induced chromosome segregation dysfunctions, even in diploid cell lines.^{112,113} Another example is that endogenous N-terminal *Apc* fragments bind to exogenous C-terminal fragments, altering the former's ability to bind to its partner Kap3.¹¹⁴ Thus, truncated *Apc* proteins could dominantly interfere with the function of the remaining allele's product. Less direct lines of evidence come from analysis of normal tissue in Min mice. For example, differences have been observed between the intestines of Min and wild type mice in enterocyte migration,¹¹⁵ E-cadherin localization,¹¹⁶ and Egfr expression.¹¹⁷ It is not yet resolved whether these effects are autonomous to the heterozygous normal tissue, or are caused by a systemic effect of the tumors carried in the Min mouse.

By contrast, a line of mice transgenic for a $\Delta 716$ or $\Delta 1287$ fragment of the *Apc* gene failed to develop intestinal tumors.¹¹⁸ Here, it is unclear whether the transgene expression levels reached a tumorigenic threshold, especially in the presence of two copies of the wild type allele. The question of whether Min is dominant negative has important implications for the study of LOH. If normal heterozygous tissue from Min animals has a phenotype that predisposes to tumorigenesis, then the familial case may differ from the sporadic case, where normal tissue is homozygous wild type for *Apc*. A full understanding of *Apc* action must also account for the full-blown polyposis phenotype of locus-wide deletions including the classical Herrera deletion by which the *APC* locus was first mapped.^{33,119,120} It is also worth noting that similar C-terminal truncations of APC2 in *Drosophila* do not exhibit dominant negative effects on Wnt signaling or viability, but in some cases do have dominant effects on cytoskeletal organization in the embryo⁹⁵. Thus, the question of predisposing haploinsufficiency or dominant negativity requires resolution.

Modifiers of murine intestinal cancer

Many different pathways have an impact on the initiation and/or progression of intestinal adenomas: karyotypic stability, DNA mutation rates, stem cell turnover, cellular growth and proliferation, cellular differentiation, environmental factors, diet, exercise, therapeutic drugs and others. In this chapter we address only genetic modifying factors (for a review of diet and therapeutic drugs, see reference 93⁹⁰). In experimental genetics, a modifying locus has no phenotypic consequence in the absence of mutation at the primary locus of interest, in this case *Apc*. In epidemiology, however, the factors controlled by modifying loci may be found to have an impact, since the functional state of the primary locus may vary covertly or overtly in the population being studied.

The phenotypic variation of Min among different inbred strains highlights the importance of modifier alleles. Historically, B6-Min mice develop approximately 100 tumors in the intestinal tract. Other inbred backgrounds on which the *Apc*^{Min} allele has been introgressed show a broad spectrum of tumor multiplicities (Table 2). For example, BTBR is a strongly enhancing background, with mice becoming moribund by 60 days of age due to the presence of more than 600 tumors.¹²¹ At the other extreme lie AKR mice, which develop only one to four tumors per animal and can survive for up to a year of age.¹²² C3H and 129S6 have milder suppressive phenotypes compared to AKR. General strain effects have led the way for the identification of polymorphic modifier loci by quantitative trait locus analysis of the phenotypes of *Min* carriers in outcrossed progeny.¹²³

Perhaps the most well-known modifier is *Mom1* (Modifier of Min 1). A quantitative trait locus (QTL) analysis using SSLP markers in crosses involving 4 inbred strains found a QTL on chromosome 4 that was shared among all mapping crosses.¹²³ It was apparent that at least two alleles of *Mom1* existed: a resistance allele found in AKR/J, MA/MyJ, and CAST/EiJ, and a sensitivity allele in C57B/6J (B6). *Mom1* is semidominant where each copy affects tumor number by a factor of about 2. MacPhee and colleagues¹²⁴ suggested that the *Pla2g2a* gene (encoding secretory phospholipase 2A) might explain the *Mom1* effect. This hypothesis was confirmed in a line of B6 Min mice transgenic for a cosmid containing the resistance allele *Pla2g2a*,¹²⁵ which showed reduced polyp number. Subsequent higher resolution genetic analysis showed that the *Mom1* locus consists of both *Pla2g2a* and at least one other distal factor.¹²⁶ The effect of *Mom1* explains a significant proportion of the variance in tumor multiplicity seen in crosses between B6-Min and AKR or C3H mice (Table 2). Interestingly, the *Pla2g2a* gene seems to act in a cell non-autonomous fashion: it is expressed from post-mitotic Paneth and goblet cells within the micro-environment, affecting the net growth rate of adjacent tumors.⁸⁵ (Evidence has been reported that the secretory phospholipase A2 can instead stimulate colonic tumor growth when expressed

autonomously within the tumor lineage.¹²⁷) The apparent non-autonomous action of *Pla2g2a* illustrates the necessity of investigations in the whole animal, as such effects would be lost in cell culture or non-orthotopic xenograft models.¹²⁸ The exact mechanism by which *Pla2g2a* exerts its effects on colon tumorigenesis remains unresolved,¹²⁹ highlighting the challenges of cancer modifier genetics. Furthermore, its relevance to the human disease is unresolved. Three studies have failed to find significant cancer-associated germline or somatic variation in the human *PLA2G2A* gene.^{130,131,132} One sporadic colon cancer patient has been reported with a constitutional frameshift mutation in this gene.¹³³ Finally, a correlation has been reported between *PLA2G2A* expression and gastric adenocarcinoma patient survival.¹³⁴ Overall, the identification of *Mom1* has had a long-lasting impact on modifier genetics, as it was an important proof of principle that such studies could identify at the molecular level genetic determinants modifying a cancer phenotype.

By utilizing similar mapping methods, additional polymorphic Modifiers of *Min* have been discovered: *Mom2*, *Mom3*, and *Mom7*, each of which resides on Chromosome 18. *Mom2* arose spontaneously in a stock of *Apc*^{Min/+} mice on the C57BL/6J background and mapped distal to the *Apc* locus.¹³⁵ Congenic line, expression, and sequencing analyses pinpointed a recessive embryonic lethal 4bp duplication in the ATP synthase *Atp5a1* gene.⁷³ When in *cis* with the mutant *Min* allele, this mutant *Mom2* allele confers an ~12-fold resistance to tumor multiplicity, but has no effect when in *trans*. Along with a decreased LOH incidence, these results indicated that somatic recombination proximal to both the *Apc* and *Atp5a1* loci would generate homozygous *Atp5a1* segregants that would be cell- and therefore tumor-lethal.

The *Mom3* locus was discovered in a line of *Min* mice that had become strain-contaminated,¹³⁶ resulting in an increase in tumor multiplicity compared to control B6-*Min* mice. It mapped to within the first 25cM of chromosome 18, proximal to *Apc*. However, the lack of additional polymorphic markers, along with the unknown contaminating strain background, prevented further positional refinement. In a separate study, the *Mom7* locus mapped to a similar region as *Mom3*, but came from defined crosses of the B6.*Apc*^{Min/+} line to the AKR, BTBR, and A/J strains.¹²¹ Congenic line and *in silico* mapping analyses reduced the *Mom7* interval to the first 4.4Mb of chromosome 18, including the complex sequence of the centromere. Unlike *Mom2*, *Mom7* is homozygous viable for all alleles and the B6 allele shows a dominant resistance phenotype in both the *trans* and *cis* configurations. Whether *Mom7* and *Mom3* represent the same underlying modifier must be resolved by complementation testing. Interestingly, the Rb(7.18)9Lub Robertsonian translocation (Rb9), also at pericentromeric Chromosome 18, lowers tumor multiplicity in *Apc*^{Min/+} mice.¹⁰⁰ FISH analysis showed that the Chromosome 18 homologs were mispaired in the nucleolar organizing region, leading to the hypothesis that the opportunity for somatic recombination at *Apc* is decreased by this centric fusion. Although *Mom7* and Rb9 map to the same location, it is important to note that Rb9 involves a gross physical chromosome abnormality, while *Mom7* involves a normal chromosome; furthermore they have qualitatively different effects, with *Mom7* resistance fully dominant and Rb9 semidominant, making it unlikely that they represent the same modifier. Furthermore, none of these modifiers shows the “overdominant effect” predicted for sequence heterozygosity, which would suppress somatic recombination in heterozygotes but not in homozygotes.¹³⁷ Thus, the *Mom7* and *Mom3* are modifiers distinct from Rb9.

As illustrated by the growing set of modifiers of the *Min* phenotype, it is clear from Table 3 that strategies for cancer prevention and therapy have many points of entry, providing both a wealth of candidate therapeutic targets and the challenge of converting any of them into potential human therapies. However, the benefit of such modifier studies extends beyond clinical relevance; each dataset informs both the functions of the modifier and of *Apc*. In

turn, each modifier has a role in processes other than tumorigenesis. For example, the increases in both karyotypic instability and tumor multiplicity in *BubR1*^{+/-}; *Apc*^{Min/+} mice provide insight into the normal checkpoint functions of both BubR1 and *Apc*.¹³⁸ Another interesting example is that deletion of *H19* induces the biallelic expression of *Igf2*, increasing Min tumor multiplicities.¹³⁹ This genetic model of loss-of-imprinting (LOI) highlights the functional importance of genomic imprinting. In human sporadic colorectal cancer patients, LOI at *Igf2* is often elevated in peripheral blood lymphocytes compared to healthy controls,¹⁴⁰ implying that LOI can precede the loss of Apc function and become a risk factor for otherwise normal individuals.

Probing deeper into the modifiers organized in Table 3, several interesting patterns are noted. First, mutations in either of the mitotic stability genes *BubR1*¹³⁸ or *Cdx2*¹⁴¹ generate a complex modifying phenotype, whereby the multiplicities of tumors of the small intestine decrease, while multiplicities of colonic tumors increase. This striking disparity between the effects of the same mutation in two different regions of the gut suggests that the small intestine and colon have different abilities to respond to CIN. Perhaps the small intestine expresses a senescence and/or apoptosis response that efficiently blocks CIN-induced tumor formation. By contrast, the hyper-recombination phenotypes of *Blm*^{142,143} or *Req1*¹⁴⁴ mutations affect the entire intestinal tract.

The contrast between the regionally diverse response to mitotic instability and the uniform response to hyperrecombinational instability suggests that different responses to different types of instability exist in different regions of the intestinal tract. In the same vein, the Mbd2 and Mbd4 methyl-binding proteins have opposite effects on intestinal tumor multiplicity,^{145,146} indicating that the epigenetic machinery has both positive and negative indirect regulators of methylation-associated DNA mutation and/or silencing. Indeed, the potency of mutations in mismatch repair genes to generate tumors in the ascending colon illustrates both the centrality of sequence stability to tumor suppression and the regionality of these effects. Next, mutations in the ephrin family of genes¹⁴⁷ demonstrate that differentiation is key to tumorigenesis, mirroring the dysregulation of ephrin receptors in mice conditionally inactivated for *Apc*.⁷⁸ Finally, many “classic” regulators of numerous tumor pathways – including p53, p27, p21, c-Jun, and cyclin D1 – modify the Min phenotype, raising the possibility that therapies directed towards other classes of cancer could also have an effect on colonic tumors.

Conclusion

The complexity of both morphological and molecular pathways in colon cancer presents a challenge to clinical therapies, which are already multifaceted. For example, the FOLFOX regimen combines fluorouracil, leucovorin, and oxaliplatin, which can be used in addition to standard surgery and radiation treatments. Despite the complexity, the many different animal models now available – mouse, rat, zebrafish, and invertebrates – expand our ability to identify and validate different therapeutic targets. Indeed, the convenience of these animal models simplifies many aspects of colon cancer research that would otherwise be difficult to control from a highly heterogeneous human population. The effectiveness of such models emerged from the discovery of Apc as the central molecule negatively regulating colon cancer. This discovery, a result of Herculean efforts by several centers of human genetics^{33,34,37,148} allowed for both the identification of the molecular basis of the Min phenotype and the characterization and construction of single-gene mutants with profound cancer phenotypes. Overall, the study of colon cancer radiates out from our understanding of the mechanisms of action of the Apc protein, a central node regulating multiple cancer pathways.

Reference List

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. *CA Cancer J Clin.* 2006; 56:106–130. [PubMed: 16514137]
2. Grosch S, Maier TJ, Schiffmann S, et al. Cyclooxygenase-2 (COX-2)-Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors. *J Natl Cancer Inst.* 2006; 98:736–747. [PubMed: 16757698]
3. O'Connell JB, Maggard MA, Ko CY. Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging. *J Natl Cancer Inst.* 2004; 96:1420–1425. [PubMed: 15467030]
4. Radtke F, Clevers H. Self-renewal and cancer of the gut: Two sides of a coin. *Science.* 2005; 307:1904–1909. [PubMed: 15790842]
5. Wasan HS, Park HS, Liu KC, et al. APC in the regulation of intestinal crypt fission. *J Pathol.* 1998; 185:246–255. [PubMed: 9771477]
6. Greaves LC, Preston SL, Tadrous PJ, et al. Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. *Proc Natl Acad Sci U S A.* 2006; 103:714–719. [PubMed: 16407113]
7. Ponder BAJ, Schmidt GH, Wilkinson MM, et al. Derivation of mouse intestinal crypts from single progenitor cells. *Nature.* 1985; 313:689–691. [PubMed: 3974703]
8. Kim KM, Shibata D. Methylation reveals a niche: stem cell succession in human colon crypts. *Oncogene.* 2002; 21:5441–5449. [PubMed: 12154406]
9. Fujita Y, Cheung AT, Kieffer TJ. Harnessing the gut to treat diabetes. *Pediatr Diabetes.* 2004; 5(Suppl 2):57–69. [PubMed: 15601375]
10. Potten CS, Morris RJ. Epithelial stem cells in vivo. *J Cell Sci Suppl.* 1988; 10:45–62. [PubMed: 3077942]
11. Cheng H, Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian theory of the origin of the four epithelial cell types. *Am J Anat.* 1974; 141:537–562. [PubMed: 4440635]
12. Potten CS. Epithelial cell growth and differentiation. II. Intestinal apoptosis. *Am J Physiol Gastrointest Liver Physiol.* 1997; 273:G253–G257.
13. Clarke MF, Fuller M. Stem cells and cancer: Two faces of Eve. *Cell.* 2006; 124:1111–1115. [PubMed: 16564000]
14. Till JE, Siminovitch L, McCulloch EA. The effect of plethora on growth and differentiation of normal hemopoietic colony-forming cells transplanted in mice of genotype W/Wv. *Blood.* 1967; 29:102–113. [PubMed: 6017601]
15. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. *Nature.* 2001; 414:105–111. [PubMed: 11689955]
16. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med.* 1997; 3:730–737. [PubMed: 9212098]
17. Al Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A.* 2003; 100:3983–3988. [PubMed: 12629218]
18. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. *Blood.* 2004; 103:2332–2336. [PubMed: 14630803]
19. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. *Cancer Res.* 2003; 63:5821–5828. [PubMed: 14522905]
20. Collins AT, Berry PA, Hyde C, et al. Prospective Identification of Tumorigenic Prostate Cancer Stem Cells. *Cancer Res.* 2005; 65:10946–10951. [PubMed: 16322242]
21. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature.* 2007; 445:106–110. [PubMed: 17122772]
22. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. *Nature.* 2006
23. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. *Nat Med.* 2006; 12:296–300. [PubMed: 16520777]

24. Shih IM, Wang TL, Traverso G, et al. Top-down morphogenesis of colorectal tumors. *Proc Natl Acad Sci U S A*. 2001; 98:2640–2645. [PubMed: 11226292]
25. Kim KM, Calabrese P, Tavare S, et al. Enhanced stem cell survival in familial adenomatous polyposis. *Am J Pathol*. 2004; 164:1369–1377. [PubMed: 15039224]
26. Wood DA, Robbins GF, Zippin C, et al. Staging of cancer of the colon and cancer of the rectum. *Cancer*. 1979; 43:961–968. [PubMed: 427737]
27. Gospodarowicz MK, Miller D, Groome PA, et al. The process for continuous improvement of the TNM classification. *Cancer*. 2004; 100:1–5. [PubMed: 14692017]
28. Bond JH. Colon Polyps and Cancer. *Endoscopy*. 2003:27–35. [PubMed: 12510223]
29. Chan TL, Zhao W, Cancer GP, et al. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. *Cancer Res*. 2003; 63:4878–4881. [PubMed: 12941809]
30. Gardner EJ. A genetic and clinical study of intestinal polyposis, a predisposing factor for carcinoma of the colon and rectum. *Am J Hum Genet*. 1951; 3:167–176. [PubMed: 14902760]
31. Shoemaker AR, Gould KA, Luongo C, et al. Studies of neoplasia in the Min mouse. *Biochim Biophys Acta*. 1997; 1332:F25–F48. [PubMed: 9141462]
32. Herrera L, Kakati S, Gibas L, et al. Brief clinical report: Gardner syndrome in a man with an interstitial deletion of 5q. *Am J Hum Genet*. 1986; 25:473–476.
33. Bodmer WF, Bailey CJ, Bodmer J, et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. *Nature*. 1987; 328:614–616. [PubMed: 3039373]
34. Kinzler KW, Nilbert MC, Su L-K, et al. Identification of FAP locus genes from chromosome 5q21. *Science*. 1991; 253:661–665. [PubMed: 1651562]
35. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutation of Chromosome 5q21 genes in FAP and colorectal cancer patients. *Science*. 1991; 253:665–668. [PubMed: 1651563]
36. Joslyn G, Carlson M, Thliveris A, et al. Identification of deletion mutations and three new genes at the familial polyposis locus. *Cell*. 1991; 66:601–613. [PubMed: 1678319]
37. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. *Cell*. 1991; 66:589–600. [PubMed: 1651174]
38. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. *Hum Mol Genet*. 2001; 10:721–733. [PubMed: 11257105]
39. Horii A, Nakatsuru S, Miyoshi Y, et al. Frequent somatic mutations of the APC gene in human pancreatic cancer. *Cancer Res*. 1992; 52:6696–6698. [PubMed: 1423316]
40. Clement G, Bosman FT, Fontollet C, et al. Monoallelic methylation of the APC promoter is altered in normal gastric mucosa associated with neoplastic lesions. *Cancer Res*. 2004; 64:6867–6873. [PubMed: 15466175]
41. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. *Science*. 1993; 262:1734–1737. [PubMed: 8259519]
42. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with β -catenin. *Science*. 1993; 262:1731–1734. [PubMed: 8259518]
43. Fearnhead NS, Wilding JL, Bodmer WF. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. *Br Med Bull*. 2002; 64:27–43. [PubMed: 12421723]
44. Noubissi FK, Elcheva I, Bhatia N, et al. CRD-BP mediates stabilization of [beta]TrCP1 and c-myc mRNA in response to [beta]-catenin signalling. *Nature*. 2006; 441:898–901. [PubMed: 16778892]
45. Harada N, Tamai Y, Ishikawa T, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. *EMBO J*. 1999; 18:5931–5942. [PubMed: 10545105]
46. Romagnolo B, Berrebi D, Saadi-Keddoucci S, et al. Intestinal dysplasia and adenoma in transgenic mice after overexpression of an activated β -catenin. *Cancer Res*. 1999; 59:3875–3879. [PubMed: 10463573]
47. Thliveris A, Samowitz W, Matsunami N, et al. Demonstration of promoter activity and alternative splicing in the region 5' to exon 1 of the APC gene. *Cancer Res*. 1994; 54:2991–2995. [PubMed: 8187087]
48. Bardos J, Sulekova Z, Ballhausen WG. Novel exon connections of the brain-specific (BS) exon of the adenomatous polyposis coli gene. *Int J Cancer*. 1997; 73:137–142. [PubMed: 9334821]

49. Pyles RB, Santoro IM, Groden J, et al. Novel protein isoforms of the APC tumor suppressor in neural tissue. *Oncogene*. 1998; 16:77–82. [PubMed: 9467945]
50. Rubinfeld B, Albert I, Porfiri E, et al. Binding of GSK3 β to the APC- β -catenin complex and regulation of complex assembly. *Science*. 1996; 272:1023–1026. [PubMed: 8638126]
51. Behrens J, Jerchow BA, Wurtele M, et al. Functional interaction of an axin homolog, conductin, with β -catenin, APC, and GSK3 β . *Science*. 1998; 280:596–599. [PubMed: 9554852]
52. Zumbunn J, Kinoshita K, Hyman AA, et al. Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3[beta] phosphorylation. *Curr Biol*. 2001; 11:44–49. [PubMed: 11166179]
53. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. *Biochim Biophys Acta*. 1997; 1332:F127–F148. [PubMed: 9196022]
54. Heppner Goss K, Trzepacz C, Tuohy TM, et al. Attenuated APC alleles produce functional protein from internal translation initiation. *Proc Natl Acad Sci U S A*. 2002; 99:8161–8166. [PubMed: 12034871]
55. Jimbo T, Kawasaki Y, Koyama R, et al. Identification of a link between the tumour suppressor APC and the kinesin superfamily. *Nat Cell Biol*. 2002; 4:323–327. [PubMed: 11912492]
56. Aoki K, Taketo MM. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. *J Cell Sci*. 2007; 120:3327–3335. [PubMed: 17881494]
57. Rowan AJ, Lamlum H, Ilyas M, et al. APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". *Proc Natl Acad Sci U S A*. 2000; 97:3352–3357. [PubMed: 10737795]
58. Albuquerque C, Breukel C, van der LR, et al. The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. *Hum Mol Genet*. 2002; 11:1549–1560. [PubMed: 12045208]
59. Crabtree M, Sieber OM, Lipton L, et al. Refining the relation between 'first hits' and 'second hits' at the APC locus: the 'loose fit' model and evidence for differences in somatic mutation spectra among patients. *Oncogene*. 2003; 22:4257–4265. [PubMed: 12833148]
60. Crabtree MD, Tomlinson IPM, Hodgson SV, et al. Explaining variation in familial adenomatous polyposis: relationship between genotype and phenotype and evidence for modifier genes. *Gut*. 2002; 51:420–423. [PubMed: 12171967]
61. Soliman AS, Bondy ML, El Badawy SA, et al. Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. *Br J Cancer*. 2001; 85:1037–1046. [PubMed: 11592777]
62. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. *Science*. 1990; 247:322–324. [PubMed: 2296722]
63. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. *Science*. 1992; 256:668–670. [PubMed: 1350108]
64. Sasai H, Masaki M, Wakitani K. Suppression of polyposis in a new mouse strain with a truncated Apc{Delta}474 by a novel COX-2 inhibitor, JTE-522. *Carcinogenesis*. 2000; 21:953–958. [PubMed: 10783317]
65. Colnot S, Niwa-Kawakita M, Hamard G, et al. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. *Lab Invest*. 2004; 84:1619–1630. [PubMed: 15502862]
66. Oshima M, Oshima H, Kitagawa K, et al. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. *Proc Natl Acad Sci U S A*. 1995; 92:4482–4486. [PubMed: 7753829]
67. Ishikawa T, Tamai Y, Li Q, et al. Requirement for tumor suppressor Apc in the morphogenesis of anterior and ventral mouse embryo. *Dev Biol*. 2003; 253:230–246. [PubMed: 12645927]
68. Niho N, Takahashi M, Kitamura T, et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. *Cancer Res*. 2003; 63:6090–6095. [PubMed: 14522940]
69. Fodde R, Edelmann W, Yang K, et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. *Proc Natl Acad Sci U S A*. 1994; 91:8969–8973. [PubMed: 8090754]

70. Smits R, Kielman MF, Breukel C, et al. Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development. *Genes Dev.* 1999; 13:1309–1321. [PubMed: 10346819]
71. Li Q, Ishikawa TO, Oshima M, et al. The threshold level of adenomatous polyposis coli protein for mouse intestinal tumorigenesis. *Cancer Res.* 2005; 65:8622–8627. [PubMed: 16204028]
72. Haigis KM, Hoff PD, White A, et al. Tumor regionality in the mouse intestine reflects the mechanism of loss of Apc function. *Proc Natl Acad Sci U S A.* 2004; 101:9769–9773. [PubMed: 15210940]
73. Baran AA, Silverman KA, Zeskand J, et al. The modifier of Min 2 (Mom2) locus: embryonic lethality of a mutation in the Atp5a1 gene suggests a novel mechanism of polyp suppression. *Genome Res.* 2007; 17:566–576. [PubMed: 17387143]
74. Gounari F, Chang R, Cowan J, et al. Loss of adenomatous polyposis coli gene function disrupts thymic development. *Nat Immunol.* 2005; 6:800–809. [PubMed: 16025118]
75. Shibata H, Toyama K, Shioya H, et al. Rapid colorectal adenoma formation initiated by conditional targeting of the *Apc* gene. *Science.* 1997; 278:120–123. [PubMed: 9311916]
76. Colnot S, Decaens T, Niwa-Kawakita M, et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. *Proc Natl Acad Sci U S A.* 2004; 101:17216–17221. [PubMed: 15563600]
77. Sansom OJ, Griffiths DF, Reed KR, et al. Apc deficiency predisposes to renal carcinoma in the mouse. *Oncogene.* 2005; 24:8205–8210. [PubMed: 16116480]
78. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. *Genes Dev.* 2004; 18:1385–1390. [PubMed: 15198980]
79. Andreu P, Colnot S, Godard C, et al. Crypt-restricted proliferation and commitment to the Paneth cell lineage following Apc loss in the mouse intestine. *Development.* 2005; 132:1443–1451. [PubMed: 15716339]
80. Sansom OJ, Meniel VS, Muncan V, et al. Myc deletion rescues Apc deficiency in the small intestine. *Nature.* 2007; 446:676–679. [PubMed: 17377531]
81. Bissahoyo A, Pearsall RS, Hanlon K, et al. Azoxymethane Is a Genetic Background-Dependent Colorectal Tumor Initiator and Promoter in Mice: Effects of Dose, Route, and Diet. *Toxicol Sci.* 2005
82. Shoemaker AR, Moser AR, Dove WF. N-ethyl-N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts. *Cancer Res.* 1995; 55:4479–4485. [PubMed: 7671263]
83. Biswas S, Chytil A, Washington K, et al. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. *Cancer Res.* 2004; 64:4687–4692. [PubMed: 15256431]
84. Oshima H, Oshima M, Kobayashi M, et al. Morphological and molecular processes of polyp formation in *Apc*^{Δ716} knockout mice. *Cancer Res.* 1997; 57:1644–1649. [PubMed: 9135000]
85. Cormier RT, Dove WF. *Dnmt1*^{N/+} reduces the net growth rate and multiplicity of intestinal adenomas in C57BL/6-*Multiple intestinal neoplasia (Min)*⁺ mice independently of *p53* but demonstrates strong synergy with the *Modifier of Min 1*^{AKR} resistance allele. *Cancer Res.* 2000; 60:3965–3970. [PubMed: 10919675]
86. Preston SL, Wong WM, Chan AO, et al. Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. *Cancer Res.* 2003; 63:3819–3825. [PubMed: 12839979]
87. Leedham S, Wright N. Expansion of a mutated clone - from stem cell to tumour. *J Clin Pathol.* 2007
88. Goodman DG, Ward JM, Squire RA, et al. Neoplastic and Nonneoplastic Lesions in Aging Osborne - Mendel Rats. *Toxicology and Applied Pharmacology.* 1980; 55:433–447. [PubMed: 7434356]
89. Miyamoto M, Takizawa S. Colon Carcinoma of Highly Inbred Rats. *J Natl Cancer Inst.* 1975; 55:1471–1472. [PubMed: 1206766]

90. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. *Eur J Cancer*. 2005; 41:1911–1922. [PubMed: 16084718]
91. Zan Y, Haag JD, Chen KS, et al. Production of knockout rats using ENU mutagenesis and a yeast-based screening assay. *Nat Biotechnol*. 2003; 21:645–651. [PubMed: 12754522]
92. Smits BM, Mudde JB, van de BJ, et al. Generation of gene knockouts and mutant models in the laboratory rat by ENU-driven target-selected mutagenesis. *Pharmacogenet Genomics*. 2006; 16:159–169. [PubMed: 16495775]
93. Amos-Landgraf JM, Kwong LN, Kendzierski CM, et al. A target-selected *Apc*-mutant rat kindred enhances the modeling of familial human colon cancer. *Proc Natl Acad Sci U S A*. 2007; 104:4036–4041. [PubMed: 17360473]
94. Haramis AP, Hurlstone A, Van DV, et al. Adenomatous polyposis coli-deficient zebrafish are susceptible to digestive tract neoplasia. *EMBO Rep*. 2006; 7:444–449. [PubMed: 16439994]
95. McCartney BM, Price MH, Webb RL, et al. Testing hypotheses for the functions of APC family proteins using null and truncation alleles in *Drosophila*. *Development*. 2006; 133:2407–2418. [PubMed: 16720878]
96. Hamada F, Murata Y, Nishida A, et al. Identification and characterization of E-APC, a novel *Drosophila* homologue of the tumour suppressor APC. *Genes to Cells*. 1999; 4:465–474. [PubMed: 10526234]
97. Rocheleau CE, Downs WD, Lin R, et al. Wnt Signaling and an APC-Related Gene Specify Endoderm in Early *C. elegans* Embryos. *Cell*. 1997; 90:707–716. [PubMed: 9288750]
98. Mizumoto K, Sawa H. Cortical beta-catenin and APC regulate asymmetric nuclear beta-catenin localization during asymmetric cell division in *C. elegans*. *Dev Cell*. 2007; 12:287–299. [PubMed: 17276345]
99. Luongo C, Moser AR, Gledhill S, et al. Loss of *Apc*⁺ in intestinal adenomas from Min mice. *Cancer Res*. 1994; 54:5947–5952. [PubMed: 7954427]
100. Haigis KM, Dove WF. A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity. *Nat Genet*. 2003; 33:33–39. [PubMed: 12447373]
101. Sieber OM, Heinemann K, Gorman P, et al. Analysis of chromosomal instability in human colorectal adenomas with two mutational hits at *APC*. *Proc Natl Acad Sci U S A*. 2002; 99:16910–16915. [PubMed: 12486240]
102. Haigis KM, Caya JG, Reichelderfer M, et al. Intestinal adenomas can develop with a stable karyotype and stable microsatellites. *Proc Natl Acad Sci U S A*. 2002; 99:8927–8931. [PubMed: 12060718]
103. Cavenee WK, Dryja TP, Phillips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. *Nature*. 1983; 305:779–784. [PubMed: 6633649]
104. Hagstrom SA, Dryja TP. Mitotic recombination map of 13cen-13q14 derived from an investigation of loss of heterozygosity in retinoblastomas. *Proc Natl Acad Sci U S A*. 1999; 96:2952–2957. [PubMed: 10077618]
105. Thiagalingam S, Laken S, Willson JK, et al. Mechanisms underlying losses of heterozygosity in human colorectal cancers. *Proc Natl Acad Sci U S A*. 2001; 98:2698–2702. [PubMed: 11226302]
106. Shih IM, Zhou W, Goodman SN, et al. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. *Cancer Res*. 2001; 61:818–822. [PubMed: 11221861]
107. Xinarianos G, McDonald FE, Risk JM, et al. Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer. *Hum Mol Genet*. 2006; 15:2038–2044. [PubMed: 16698880]
108. Cardoso J, Molenaar L, de Menezes RX, et al. Chromosomal instability in MYH- and APC-mutant adenomatous polyps. *Cancer Res*. 2006; 66:2514–2519. [PubMed: 16510566]
109. Nowak MA, Komarova NL, Sengupta A, et al. The role of chromosomal instability in tumor initiation. *Proc Natl Acad Sci U S A*. 2002; 99:16226–16231. [PubMed: 12446840]
110. Komarova NL, Wodarz D. The optimal rate of chromosome loss for the inactivation of tumor suppressor genes in cancer. *Proc Natl Acad Sci U S A*. 2004; 101:7017–7021. [PubMed: 15105448]

111. Tomlinson IPM, Novelli MR, Bodmer WF. The mutation rate and cancer. *Proc Natl Acad Sci U S A*. 1996; 93:14800–14803. [PubMed: 8962135]
112. Green RA, Kaplan KB. Chromosome instability in colorectal tumor cells is associated with defects in microtubule plus-end attachments caused by a dominant mutation in APC. *The Journal of Cell Biology*. 2003; 163:949–961. [PubMed: 14662741]
113. Tighe A, Johnson VL, Taylor SS. Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability. *J Cell Sci*. 2004; 117:6339–6353. [PubMed: 15561772]
114. Li Z, Nathke IS. Tumor-associated NH₂-terminal fragments are the most stable part of the adenomatous polyposis coli protein and can be regulated by interactions with COOH-terminal domains. *Cancer Res*. 2005; 65:5195–5204. [PubMed: 15958564]
115. Mahmoud NN, Boolbol SK, Bilinski RT, et al. Apc Gene Mutation Is Associated with a Dominant-Negative Effect upon Intestinal Cell Migration. *Cancer Res*. 1997; 57:5045–5050. [PubMed: 9371501]
116. Carothers AM, Melstrom KA Jr, Mueller JD, et al. Progressive changes in adherens junction structure during intestinal adenoma formation in Apc mutant mice. *J Biol Chem*. 2001; 276:39094–39102. [PubMed: 11483600]
117. Moran AE, Hunt DH, Javid SH, et al. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. *J Biol Chem*. 2004; 279:43261–43272. [PubMed: 15294912]
118. Oshima M, Oshima H, Kobayashi M, et al. Evidence against dominant negative mechanisms of intestinal polyp formation by Apc gene mutations. *Cancer Res*. 1995; 55:2719–2722. [PubMed: 7796392]
119. Sieber OM, Lamlum H, Crabtree MD, et al. Whole-gene APC deletions cause classical familial adenomatous polyposis, but not attenuated polyposis or "multiple" colorectal adenomas. *Proc Natl Acad Sci U S A*. 2002; 99:2954–2958. [PubMed: 11867715]
120. Michils G, Tejpar S, Thoelen R, et al. Large deletions of the APC gene in 15% of mutation-negative patients with classical polyposis (FAP): a Belgian study. *Hum Mutat*. 2005; 25:125–134. [PubMed: 15643602]
121. Kwong LN, Shedlovsky A, Biehl BS, et al. Identification of Mom7, a novel modifier of *Apc*^{Min/+} on mouse Chromosome 18. *Genetics*. 2007; 176:1237–1244. [PubMed: 17435219]
122. Shoemaker AR, Moser AR, Midgley CA, et al. A resistant genetic background leading to incomplete penetrance of intestinal neoplasia and reduced loss of heterozygosity in *Apc*^{Min/+} mice. *Proc Natl Acad Sci U S A*. 1998; 95:10826–10831. [PubMed: 9724789]
123. Dietrich WF, Lander ES, Smith JS, et al. Genetic identification of *Mom-1*, a major modifier locus affecting *Min*-induced intestinal neoplasia in the mouse. *Cell*. 1993; 75:631–639. [PubMed: 8242739]
124. MacPhee M, Chepenik KP, Liddell RA, et al. The secretory phospholipase A2 gene is a candidate for the *Mom1* locus, a major modifier of *Apc*^{Min}-induced intestinal neoplasia. *Cell*. 1995; 81:957–966. [PubMed: 7781071]
125. Cormier RT, Hong KH, Halberg RB, et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. *Nat Genet*. 1997; 17:88–91. [PubMed: 9288104]
126. Cormier RT, Bilger A, Lillich AJ, et al. The *Mom1*^{AKR} intestinal tumor resistance region consists of *Pla2g2a* and a locus distal to *D4Mit64*. *Oncogene*. 2000; 19:3182–3192. [PubMed: 10918573]
127. Belinsky GS, Rajan TV, Saria EA, et al. Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth. *Mol Carcinog*. 2007; 46:106–116. [PubMed: 17091473]
128. Dove W. Aurora and the hunt for cancer-modifying genes. *Nat Genet*. 2003; 34:353–354. [PubMed: 12923537]
129. Chan TA, Morin PJ, Vogelstein B, et al. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. *Proc Natl Acad Sci U S A*. 1998; 95:681–686. [PubMed: 9435252]
130. Tomlinson IP, Beck NE, Neale K, et al. Variants at the secretory phospholipase A2 (PLA2G2A) locus: analysis of associations with familial adenomatous polyposis and sporadic colorectal tumours. *Ann Hum Genet*. 1996; 60(Pt 5):369–376. [PubMed: 8912789]

131. Spirio LN, Kutchera W, Winstead MV, et al. Three secretory phospholipase A₂ genes that map to human chromosome 1P35-36 are not mutated in individuals with attenuated adenomatous polyposis coli. *Cancer Res.* 1996; 56:955–958. [PubMed: 8640784]
132. Riggins GJ, Markowitz S, Wilson JK, et al. Absence of secretory phospholipase A₂ gene alterations in human colorectal cancer. *Cancer Res.* 1995; 55:5184–5186. [PubMed: 7585570]
133. Nimmrich I, Friedl W, Kruse R, et al. Loss of the PLA2G2A gene in a sporadic colorectal tumor of a patient with a PLA2G2A germline mutation and absence of PLA2G2A germline alterations in patients with FAP. *Hum Genet.* 1997; 100:345–349. [PubMed: 9272153]
134. Leung SY, Chen X, Chu KM, et al. Phospholipase A₂ group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. *Proc Natl Acad Sci U S A.* 2002; 99:16203–16208. [PubMed: 12456890]
135. Silverman KA, Koratkar R, Siracusa LD, et al. Identification of the modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced intestinal neoplasia. *Genome Res.* 2002; 12:88–97. [PubMed: 11779834]
136. Haines J, Johnson V, Pack K, et al. Genetic basis of variation in adenoma multiplicity in ApcMin/+ Mom1S mice. *Proc Natl Acad Sci U S A.* 2005; 102:2868–2873. [PubMed: 15710876]
137. Shao C, Stambrook PJ, Tischfield JA. Mitotic recombination is suppressed by chromosomal divergence in hybrids of distantly related mouse strains. *Nat Genet.* 2001; 28:169–172. [PubMed: 11381266]
138. Rao CV, Yang YM, Swamy MV, et al. Colonic tumorigenesis in BubR1+/-ApcMin/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. *PNAS.* 2005; 102:4365–4370. [PubMed: 15767571]
139. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. *Science.* 2005; 307:1976–1978. [PubMed: 15731405]
140. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: A potential marker of colorectal cancer risk. *Science.* 2003; 299:1753–1755. [PubMed: 12637750]
141. Aoki K, Tamai Y, Horiike S, et al. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice. *Nat Genet.* 2003; 35:323–330. [PubMed: 14625550]
142. Goss KH, Risinger MA, Kordich JJ, et al. Enhanced tumor formation in mice heterozygous for Blm mutation. *Science.* 2002; 297:2051–2053. [PubMed: 12242442]
143. Luo G, Santoro IM, McDaniel LD, et al. Cancer predisposition caused by elevated mitotic recombination in Bloom mice. *Nat Genet.* 2000; 26:424–429. [PubMed: 11101838]
144. Mann MB, Hodges CA, Barnes E, et al. Defective sister-chromatid cohesion, aneuploidy and cancer predisposition in a mouse model of type II Rothmund-Thomson syndrome. *Hum Mol Genet.* 2005; 14:813–825. [PubMed: 15703196]
145. Sansom OJ, Berger J, Bishop SM, et al. Deficiency of Mbd2 suppresses intestinal tumorigenesis. *Nat Genet.* 2003; 34:145–147. [PubMed: 12730693]
146. Millar CB, Guy J, Sansom OJ, et al. Enhanced CpG Mutability and Tumorigenesis in MBD4-Deficient Mice. *Science.* 2002; 297:403–405. [PubMed: 12130785]
147. Batlle E, Bacani J, Begthel H, et al. EphB receptor activity suppresses colorectal cancer progression. *Nature.* 2005; 435:1126–1130. [PubMed: 15973414]
148. Leppert M, Dobbs M, Scambler P, et al. The gene for familial polyposis coli maps to the long arm of chromosome 5. *Science.* 1987; 238:1411–1413. [PubMed: 3479843]
149. Oshima M, Oshima H, Kitagawa K, et al. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. *Proc Natl Acad Sci U S A.* 1995; 92:4482–4486. [PubMed: 7753829]
150. Ishikawa TO, Jain NK, Taketo MM, et al. Imaging cyclooxygenase-2 (Cox-2) gene expression in living animals with a luciferase knock-in reporter gene. *Mol Imaging Biol.* 2006; 8:171–187. [PubMed: 16557423]
151. Koratkar R, Silverman KA, Pequignot E, et al. Analysis of reciprocal congenic lines reveals the C3H/HeJ genome to be highly resistant to Apc^{Min} intestinal tumorigenesis. *Genomics.* 2004; 84:844–852. [PubMed: 15475263]

152. Koratkar R, Pequignot E, Hauck WW, et al. The CAST/Ei strain confers significant protection against *Apc*^{Min} intestinal polyps, independent of the resistant Modifier of Min 1 (*Mom1*^R) locus. *Cancer Res.* 2002; 62:5413–5417. [PubMed: 12359746]
153. Rudolph KL, Millard M, Bosenberg MW, et al. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. *Nat Genet.* 2001; 28:155–159. [PubMed: 11381263]
154. Baker SM, Harris AC, Tsao JL, et al. Enhanced intestinal adenomatous polyp formation in *Pms2*^{-/-}; *Min* mice. *Cancer Res.* 1998; 58:1087–1089. [PubMed: 9515784]
155. Shoemaker AR, Haigis KM, Baker SM, et al. *Mlh1* deficiency enhances several phenotypes of *Apc*^{Min/+} mice. *Oncogene.* 2000; 19:2774–2779. [PubMed: 10851078]
156. Reitmair AH, Cai JC, Bjerknes M, et al. *MSH2* deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. *Cancer Res.* 1996; 56:2922–2926. [PubMed: 8674041]
157. Kuraguchi M, Yang K, Wong E, et al. The distinct spectra of tumor-associated *Apc* mutations in mismatch repair-deficient *Apc*^{1638N} mice define the roles of *MSH3* and *MSH6* in DNA repair and intestinal tumorigenesis. *Cancer Res.* 2001; 61:7934–7942. [PubMed: 11691815]
158. Kucheralapati M, Yang K, Kuraguchi M, et al. Haploinsufficiency of Flap endonuclease (*Fen1*) leads to rapid tumor progression. *PNAS.* 2002; 99:9924–9929. [PubMed: 12119409]
159. Sieber OM, Howarth KM, Thirlwell C, et al. *Myh* deficiency enhances intestinal tumorigenesis in multiple intestinal neoplasia (*Apc*^{Min/+}) mice. *Cancer Res.* 2004; 64:8876–8881. [PubMed: 15604247]
160. Perreault N, Sackett SD, Katz JP, et al. *Foxl1* is a mesenchymal Modifier of Min in carcinogenesis of stomach and colon. *Genes and Development.* 2005; 19:311–315. [PubMed: 15650110]
161. Gutierrez LS, Suckow M, Lawler J, et al. Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the *APC*^{Min/+} mouse model. *Carcinogenesis.* 2003; 24:199–207. [PubMed: 12584168]
162. Nateri AS, Spencer-Dene B, Behrens A. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. *Nature.* 2005; 437:281–285. [PubMed: 16007074]
163. Hult J, Wang C, Li Z, et al. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in *Apc*^{Min} mice. *Mol Cell Biol.* 2004; 24:7598–7611. [PubMed: 15314168]
164. Roberts RB, Min L, Washington MK, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. *Proc Natl Acad Sci U S A.* 2002; 99:1521–1526. [PubMed: 11818567]
165. Yang WC, Mathew J, Velcich A, et al. Targeted Inactivation of the p21WAF1/cip1 Gene Enhances *Apc*-initiated Tumor Formation and the Tumor-promoting Activity of a Western-Style High-Risk Diet by Altering Cell Maturation in the Intestinal Mucosa. *Cancer Res.* 2001; 61:565–569. [PubMed: 11212250]
166. Philipp-Staheli J, Kim KH, Payne SR, et al. Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in *Apc* mutant mice, but not in *Smad3* mutant mice. *Cancer Cell.* 2002; 1:355–368. [PubMed: 12086850]
167. Halberg RB, Katzung DS, Hoff PD, et al. Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. *Proc Natl Acad Sci U S A.* 2000; 97:3461–3466. [PubMed: 10716720]
168. Wilson CL, Heppner KJ, Labosky PA, et al. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. *Proc Natl Acad Sci U S A.* 1997; 94:1402–1407. [PubMed: 9037065]
169. Dinchuk JE, Focht RJ, Kelley JA, et al. Absence of post-translational aspartyl β-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. *J Biol Chem.* 2002; 277:12970–12977. [PubMed: 11773073]
170. Smits R, Ruiz P, Diaz-Cano S, et al. E-cadherin and adenomatous polyposis coli mutations are synergistic in intestinal tumor initiation in mice. *Gastroenterology.* 2000; 119:1045–1053. [PubMed: 11040191]
171. Harman FS, Nicol CJ, Marin HE, et al. Peroxisome proliferator-activated receptor-[delta] attenuates colon carcinogenesis. *Nat Med.* 2004; 10:481–483. [PubMed: 15048110]

172. Mazelin L, Bernet A, Bonod-Bidaud C, et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. *Nature*. 2004; 431:80–84. [PubMed: 15343335]
173. Takaku K, Miyoshi H, Matsunaga A, et al. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. *Cancer Res*. 1999; 59:6113–6117. [PubMed: 10626800]
174. Ruivenkamp CAL, Csikos T, Klous AM, et al. Five new mouse susceptibility to colon cancer loci, Sccl1-Sccl5. *Oncogene*. 2003; 22:7258–7260. [PubMed: 14562056]




Figure 1. Organization of the mouse, rat, and human chromosomes bearing the *APC/Apc* and *Mom7* orthologs

A) The *Apc* locus of the mouse lies on a telocentric chromosome, in contrast to its orthologs in the rat and human, each of which lies on a metacentric chromosome. A metacentric character enables a facile discrimination between whole chromosome loss *versus* somatic recombination. B) The *APC/Apc* locus of the mouse is linked to the *Mom7* locus on Chr 18, while the orthologs of these two loci are not linked in the rat and human karyotypes.




Figure 2. The structure of the Apc protein

Arrows indicate orthologous locations of mouse model mutations and the two most common FAP mutation sites. The color bar below indicates the genotype-phenotype correlation of sites of protein truncation to disease severity. The data used to generate the color bar can be found at <http://www.mcardle.wisc.edu/dove/Data/Apc.htm>.

Table 1

Apc mutant mouse lines

Allele	Truncation codon	Conditional?	Genetic Background	Intestinal Tumor #	% of wt protein per allele	Initial Reference of Phenotype
Δ468	468 (armadillo repeats)	Yes	N/Av	N/Av	N/Av	Gounari et al., 2005 ⁷⁴
Δ474	474 (armadillo repeats)	No	B6	>100	100	Sasai et al., 2000 ⁶⁴
Δ14	580 (armadillo repeats)	Yes	B6	>100	100	Colnot et al., 2004 ⁶⁵
580S	580 (armadillo repeats)	Yes	Mixed	N/Av	N/Av	Shibata et al., 1997 ⁷⁵
Δ716	716 (armadillo repeats)	No	B6	>100	0*	Oshima et al., 1995 ¹⁴⁹
lacZ	716 (armadillo repeats)	No	Mixed	>100	100	Ishikawa et al., 2006 ¹⁵⁰
Min	850 (armadillo repeats)	No	B6	>100	100	Moser et al., 1990 ⁶²
Δ1309	1309 (15aa repeats)	No	B6	40	100	Niho et al., 2003 ⁶⁸
1638N	1638 (SAMP repeats)	No	B6	1	2	Fodde et al., 1994 ⁶⁹
1638T	1638 (SAMP repeats)	No	B6	0	100	Smits et al., 1999 ⁷⁰
Ex13 NeoR	full-length	No	B6	1	20	Li et al., 2005 ⁷¹
Ex13 NeoF	full-length	No	B6	0.3	10	Li et al., 2005 ⁷¹

* This is suggested, but not proven.⁷¹

N/Av = not available.

Table 2

The genetic background dependence of the Min phenotype

Strain	Mom1	Age (days)	Small Intestine	Colon	N	Reference
129S6	S/S	103–163	45	1	23	L.N. Kwong, unpublished
BTBR/Pas	S/S	54–82	625	12	74	Kwong et al., 2007 ¹²¹
C3H/HeJ	S/S	100–120	16	0.4	89	Koratkar et al., 2004 ¹⁵¹
C57BL/6J	S/S	90–120	128	3	48	Kwong et al., 2007 ¹²¹
AKR/J	R/R	146–336	4	0	42	Kwong et al., 2007 ¹²¹
129 × B6 F1	S/S	92–164	82	0.2	35	L.N. Kwong, unpublished
AKR × B6 F1	R/S	104–143	25	0.1	15	Kwong et al., 2007 ¹²¹
BTBR × B6 F1 *	S/S	80–93	117	1.6	16	A. Shedlovsky, unpublished
BTBR × B6 F1 **	S/S	84–89	215	1.4	19	A. Shedlovsky, unpublished
C3H × B6 F1	R/S	130–150	8	0	10	Koratkar et al., 2004 ¹⁵¹
CAST × B6 F1	R/S	100–120	3	0	14	Koratkar et al., 2002 ¹⁵²
CAST × B6 F1	R/S	185–215	7	0	11	Koratkar et al., 2002 ¹⁵²

* Min from B6 parent

** Min from BTBR parent

Table 3

Molecular genetic modifiers of *Apc* knockout mouse models

Modifier affects	Modifier gene(s)	Modifier allele(s)	Allele property	Apc Model	Effect of mutant allele on intestinal tumor multiplicity	Factor of effect	Reference
Karyotypic stability	BubR1	Bub1b ^{Gt(neo-btk)1Dai}	Knockout (het)	Min	Decrease/Increase ^a	2/10 ^a	Rao et al., 2005 ¹³⁸
	Cdx2	Cdx2 ^{tm1Mmt}	Knockout (het)	Δ716	Decrease/Increase ^a	9/6 ^a	Aoki et al., 2003 ¹⁴¹
	Terc	Terc ^{tm1Rdp}	Knockout	Min	Decrease (at G4)	10	Rudolph et al., 2001 ¹⁵³
DNA mutation rate	Pms2	Pms2 ^{tm1Lisk}	Knockout	Min	Increase	3	Baker et al., 1998 ¹⁵⁴
	Mlh1	Mlh1 ^{tm1Lisk}	Knockout	Min	Increase	3	Shoemaker et al., 2000 ¹⁵⁵
	Msh2	Msh2 ^{tm1Mak}	Knockout	Min	Increase	7	Reitmair et al., 1996 ¹⁵⁶
	Msh3/ Msh6	Msh3 ^{tm1Rak} Msh6 ^{tm1Rak}	Knockout	1638N	Increase	12	Kuraguchi et al., 2001 ¹⁵⁷
	Fen1	Fen1 ^{tm1Rak}	Knockout (het)	1638N	Increase	1.5	Kucherlapati et al., 2002 ¹⁵⁸
	Myh	Mutyh ^{tm1Jhmi}	Knockout	Min	Increase	1.5	Sieber et al., 2004 ¹⁵⁹
Recombination rates	Rb9	Rb(7.18)9Lub	Translocation	Min	Decrease	19	Haigis and Dove, 2003 ¹⁰⁰
	Recq14	Recq14 ^{tm1Glu}	Knockout	Min	Increase	2	Mann et al., 2005 ¹⁴⁴
	Blm	Blm ^{tm3Brd}	Hypomorph	Min	Increase	3	Luo et al., 2000 ¹⁴³
Differentiation	EphB2	Δ ^{cy} EphB2	Dom neg Tg	Min	Decrease	3	Battle et al., 2005 ¹⁴⁷
	EphB3	EphB3 ^{tm1Kln}	Knockout	Min	Increase	2	Battle et al., 2005 ¹⁴⁷
DNA methylation	Mbd2	Mbd2 ^{tm1Bh}	Knockout	Min	Decrease	10	Sansom et al., 2003 ¹⁴⁵
	Mbd4	Mbd4 ^{tm1Bird}	Knockout	Min	Increase	2	Millar et al., 2002 ¹⁴⁶
	Dnmt1	Dnmt1 ^{tm1Jae}	Knockout (het)	Min	Decrease	2	Cormier and Dove, 2000 ⁸⁵
Stromal regulation	Foxl1	Foxl1 ^{tm1Khk}	Knockout	Min	Increase	8	Perrault et al., 2005 ¹⁶⁰
	TSP1	Thbs1 ^{tm1Hyn}	Knockout	Min	Increase	2	Gutierrez et al., 2003 ¹⁶¹
Cell growth and proliferation	c-Jun	Jun ^{tm2.1Wag}	Hypomorph	Min	Decrease	2	Nateri et al., 2005 ¹⁶²
	Cyclin D1	Ccnd1 ^{tm1Wbg}	Knockout	Min	Decrease	6	Hulit et al., 2004 ¹⁶³
	Egfr	Egfr ^{wa2}	Hypomorph	Min	Decrease	10	Roberts et al., 2002 ¹⁶⁴

Modifier affects	Modifier gene(s)	Modifier allele(s)	Allele property	Apc Model	Effect of mutant allele on intestinal tumor multiplicity	Factor of effect	Reference
	p21	Cdkn1a ^{tm1Led}	Knockout	1638N	Increase	2	Yang et al., 2001 ¹⁶⁵
	p27	Cdkn1b ^{tm1Mlf}	Knockout	Min	Increase	5	Philipp-Staheli et al., 2002 ¹⁶⁶
	p53	Trp53 ^{tm1Ldo}	Knockout	Min	Increase	2	Halberg et al., 2000 ¹⁶⁷
	Igf2	H19 ^{tm1Tilg}	Activates Igf2	Min	Increase	2	Sakatani et al., 2005 ¹³⁹
Pleiotropic	Matrilysin	Mmp7 ^{tm1Lmm}	Knockout	Min	Decrease	2	Wilson et al., 1997 ¹⁶⁸
	Pla2g2a	Pla2g2a ^{AKR}	Tg	Min	Decrease	2	Cormier et al., 1997 ¹²⁵
	BAH	Asph ^{tm1Jed}	Knockout	Min	Increase	2	Dinchuk et al., 2002 ¹⁶⁹
	E-cadherin	Cdh1 ^{tm1Cbm}	Knockout (het)	1638N	Increase	9	Smits et al., 2000 ¹⁷⁰
	PPAR- δ	Ppard ^{tm1Jps}	Knockout	Min	Increase	1.5	Harman et al., 2004 ¹⁷¹
	Netrin-1	Tg-netrin-1	Tg	1638N	Enhances progression	N/A	Mazelin et al., 2004 ¹⁷²
	Smad4	Smad4 ^{tm1Mmt}	Knockout	Δ 716	Enhances progression	N/A	Takaku et al., 1999 ¹⁷³

^aEffects on the small intestine and colon, respectively ;

^bThe Robertsonian translocation is centromeric fusion of chromosomes 7 and 18.

Note: The *Mom* (Modifier of Min) and *Scc* (Susceptibility to colon cancer)¹⁷⁴ loci are in general not yet fully defined in molecular detail (see text) and are therefore not included in Table 3.